New Depression Treatment Targets the Immune System Instead of the Brain
The 30-person trial found higher remission rates and lower fatigue with tocilizumab, but the small study did not reach statistical significance.
4 Articles
4 Articles
New depression treatment targets the immune system instead of the brain
A surprising new approach to depression treatment is showing early promise — not by targeting brain chemicals, but by calming the immune system. In a small clinical trial, researchers found that an anti-inflammatory drug normally used for rheumatoid arthritis appeared to ease symptoms in people with hard-to-treat depression, while also reducing fatigue and anxiety and improving quality of life.
Clinical trial suggests an anti-inflammatory drug could relieve difficult-to-treat depression
A recent clinical trial suggests that treating the immune system with an anti-inflammatory drug could relieve symptoms in people with difficult-to-treat depression. The research provides early evidence that lowering inflammation levels tends to improve mood, fatigue, and anxiety for these individuals. The findings were published in the medical journal JAMA Psychiatry. Standard medical treatments for depression typically focus on brain chemistry.…
A clinical study led by the University of Bristol has opened a fundamentally new direction in the treatment of depression.
Researchers at the University of Bristol have presented a new approach to treating depression, focusing on the immune system rather than just neurotransmitters in the brain. A recent clinical trial revealed that tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, can alleviate symptoms in patients with depression resistant to conventional treatment. New approach to treating depression The clinical trial, published in the j…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
